...
首页> 外文期刊>Journal of cataract and refractive surgery >Pharmacologic pupil dilation as a predictive test for the risk for intraoperative floppy-iris syndrome.
【24h】

Pharmacologic pupil dilation as a predictive test for the risk for intraoperative floppy-iris syndrome.

机译:药理学瞳孔扩张作为术中软盘虹膜综合征风险的预测测试。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: To evaluate the effect of alpha1-adrenergic receptor antagonists (alpha1-ARAs) on pupil diameter and determine whether the diameter predicts intraoperative floppy-iris syndrome (IFIS). SETTING: Ophthalmology Section, Palermo University, Palermo, Italy. DESIGN: Prospective cohort study. METHODS: Male outpatients taking tamsulosin, alpha(1)-ARAs, or no alpha(1)-ARAs having phacoemulsification were recruited. Pupils were measured 1 month preoperatively, immediately preoperatively, and postoperatively under mesopic low (0.4 lux) and high (4.0 lux) illumination after pharmacologic dilation. The IFIS severity was graded. RESULTS: Each group comprised 50 patients. Pharmacologic dilation in both alpha(1)-ARA groups was statistically significantly less than in the no alpha1-ARA group 1 month preoperatively, immediately before surgery, and postoperatively (P=.001, P<.0005, and P<.0005, respectively). The IFIS incidence differed significantly between the tamsulosin and other alpha(1)-ARA groups and the no alpha1-ARA group (P<.0005 and P=.017, respectively) and between the tamsulosin group and the other alpha1-ARA group (P=.027). On regression analysis, the hazard ratio for overall IFIS incidence was 3.8 in the other alpha(1)-ARA group (P=.012) and 10.1 in the tamsulosin group (P<.0005). Pupil size was inversely related to IFIS incidence and severity (P<.0005). A dilated pupil of 7.0 mm or smaller had 73% sensitivity and 95% specificity for predicting IFIS (P=.0001). CONCLUSIONS: Pupil dilation was inhibited by alpha(1)-ARAs, in particular tamsulosin. For a pupil 7.0 mm or smaller, the risk for IFIS existed regardless of alpha(1)-ARAs treatment, which surgeons should take into consideration.
机译:目的:评估α1-肾上腺素能受体拮抗剂(α1-ARAs)对瞳孔直径的影响,并确定该直径是否可预测术中软盘虹膜综合症(IFIS)。地点:意大利巴勒莫大学巴勒莫大学眼科。设计:前瞻性队列研究。方法:招募接受坦索罗辛,α(1)-ARA或不进行超声乳化的α(1)-ARA的男性门诊患者。术前,术前和术后1个月分别在药理性扩张后的中视低(0.4 lux)和高(4.0 lux)光照下对学生进行测量。 IFIS严重性分级。结果:每组包括50例患者。术前1个月,术前和术后1个月,两个alpha(1)-ARA组的药理学膨胀均显着低于noalpha1-ARA组(P = .001,P <.0005和P <.0005,分别)。坦索罗辛组与其他alpha(1)-ARA组和无alpha1-ARA组之间的IFIS发生率显着不同(分别为P <.0005和P = .017)以及坦索罗辛组与另一alpha1-ARA组之间的IFIS发生率( P = .027)。通过回归分析,其他alpha(1)-ARA组的IFIS总体发生风险比为3.8(P = .012),坦索罗辛组为10.1(P <.0005)。学生大小与IFIS发生率和严重程度成反比(P <.0005)。 7.0毫米或更小的散瞳在预测IFIS方面具有73%的灵敏度和95%的特异性(P = .0001)。结论:瞳孔的扩张受到α(1)-ARAs,特别是坦洛新的抑制。对于7.0毫米或更小的瞳孔,无论采用alpha(1)-ARAs治疗如何,都存在IFIS的风险,应考虑哪些外科医生。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号